Source: European Medicines Agency (EU) Revision Year: 2023 Publisher: PAION Deutschland GmbH, Heussstraße 25, 52078 Aachen, Germany
Xerava 100 mg powder for concentrate for solution for infusion.
| Pharmaceutical Form |
|---|
|
Powder for concentrate for solution for infusion (powder for concentrate). Pale yellow to dark yellow cake. |
Each vial contains 100 mg eravacycline.
After reconstitution, each mL contains 20 mg eravacycline.
After further dilution, 1 mL contains 0.6 mg eravacycline.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Eravacycline |
Eravacycline is an antibacterial drug. Its mechanism of action involves the disruption of bacterial protein synthesis by binding to the 30S ribosomal subunit thus preventing the incorporation of amino acid residues into elongating peptide chains. |
| List of Excipients |
|---|
|
Mannitol (E421) |
10 mL Type I glass vial with butyl rubber stopper and aluminium cap.
Pack sizes: 1 vial, 10 vials and multipacks containing 12 (12 packs of 1) vials.
Not all pack sizes may be marketed.
PAION Deutschland GmbH, Heussstraße 25, 52078 Aachen, Germany
EU/1/18/1312/003
EU/1/18/1312/004
EU/1/18/1312/005
Date of first authorisation: 20 September 2018
| Drug | Countries | |
|---|---|---|
| XERAVA | Austria, Estonia, France, Croatia, Ireland, Italy, Lithuania, Poland, Romania, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
